DAFTAR PUSTAKA

Adeel Rehman, Kumayl Abbas Meghji, Haji Abdullah Memon, Ahmed Mustafa Burney, Wasi Ur Rehman Siyal, & Muhammad Jawad. (2024). Correlation between hepatomegaly and transfusion frequency in thalassemia patients: A cross-sectional study. *The Professional Medical Journal*, *31*(02), 277–282. https://doi.org/10.29309/tpmj/2024.31.02.7729

Ahmed, M. H., Ghatge, M. S., & Safo, M. K. (2020). Hemoglobin: Structure, Function and Allostery. In *Subcellular Biochemistry* (Vol. 94, pp. 345–382). Springer. https://doi.org/10.1007/978-3-030-41769-7_14

Andika, O., & Puspitasari, A. ; (2019). *Buku Ajar Mata Kuliah Hematologi Diterbitkan oleh UMSIDA PRESS*.

Anggoro, A. (2017). *Talasemia pada Kehamilan* (Vol. 1).

Ansari-Moghaddam, A., Adineh, H. A., Zareban, I., Mohammadi, M., & Maghsoodlu, M. (2018). The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran. *Epidemiology and Health*, *40*. https://doi.org/10.4178/epih.e2018048

Arfie, N. G., Zulkarnaen, B. S., & Sudarmanto, S. (2022). Efektivitas Deferasirox pada Pasien Thalasemia Mayor: Artikel Review. *Jurnal Sains Dan Kesehatan*, *4*(3), 354–362. https://doi.org/10.25026/jsk.v4i3.1159

Armina, A., & Pebriyanti, D. K. (2021). Hubungan Kepatuhan Transfusi Darah dan Kelasi Besi dengan Kualitas Hidup Anak Thalasemia. *Jurnal Akademika Baiturrahim Jambi*, *10*(2), 306. https://doi.org/10.36565/jab.v10i2.336

Asadov, C., Alimirzoeva, Z., Mammadova, T., Aliyeva, G., Gafarova, S., & Mammadov, J. (2018). β-Thalassemia intermedia: a comprehensive overview and novel approaches. *International Journal of Hematology*, *108*(1), 5–21. https://doi.org/10.1007/s12185-018-2411-9

Babker, A. M. A. (2022). An overview on thalassemia and challenges during COVID-19. *International Journal of Health Sciences*, 3207–3220. https://doi.org/10.53730/ijhs.v6ns1.5446

Bodge, M., & Cumpston, A. (2019). Pharmacology of Drugs Used in Hematopoietic Cell Transplantation. In *Hematopoietic Cell Transplantation for Malignant Conditions* (pp. 19–35). Elsevier. https://doi.org/10.1016/B978-0-323-56802-9.00002-X

Bouguila, J., Besbes, G., & Khochtali, H. (2015). Skeletal facial deformity in patients with β thalassemia major: Report of one Tunisian case and a review of the literature. *International Journal of Pediatric Otorhinolaryngology*, *79*(11), 1955–1958. https://doi.org/10.1016/j.ijporl.2015.08.037

Calderon Moreno, R., Navas-Acien, A., Escolar, E., Nathan, D. M., Newman, J., Schmedtje, J. F., Diaz, D., Lamas, G. A., & Fonseca, V. (2019). Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes. In *Journal of Clinical Endocrinology and Metabolism* (Vol. 104, Issue 7, pp. 2931–2941). Endocrine Society. https://doi.org/10.1210/jc.2018-01484

Chiabrando, D., Mercurio, S., & Tolosano, E. (2014). Heme and erythropoieis: More than a structural role. In *Haematologica* (Vol. 99, Issue 6, pp. 973–983). Ferrata Storti Foundation. https://doi.org/10.3324/haematol.2013.091991

Clénin, G. E., Cordes, M., Huber, A., Schumacher, Y., Noack, P., Scales, J., & Kriemler, S. (2016). Iron deficiency in sports - definition, influence on performance and

therapy. *Schweizerische Zeitschrift Fur Sportmedizin Und Sporttraumatologie*, *64*(1), 6–18. https://doi.org/10.4414/smw.2015.14196

Dorgaleleh, S., Barahouie, A., Naghipoor, K., Dastaviz, F., Ghodsalavi, Z., & Oladnabi, M. (2020). Transfusion Related Adverse Effects on Beta-Thalassemia Major and New Therapeutic Approaches: A Review Study. *Int J Pediatr*, *8*(79). https://doi.org/10.22038/ijp.2020.46749.3794

Edi, I. G. M. S. (2017). *FAKTOR-FAKTOR YANG MEMPENGARUHI KEPATUHAN PASIEN PADA PENGOBATAN: TELAAH SISTEMATIK (FACTORS AFFECTING THE PATIENT ADHERENCE TO MEDICAL TREATMENT: A SYSTEMATIC REVIEW)*.

Elalfy, M. S., Hamdy, M., Adly, A., Ebeid, F. S. E., Temin, N. T., Rozova, A., Lee, D., Fradette, C., & Tricta, F. (2023). Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START). *American Journal of Hematology*, *98*(9), 1415–1424. https://doi.org/10.1002/ajh.27010

Eleftheriou, A., & Angastiniotis, M. (2023). *GLOBAL EPIDEMIOLOGY OF B-THALASSAEMIA*. www.thalassaemia.org.cy

Entezari, S., Haghi, S. M., Norouzkhani, N., Sahebnazar, B., Vosoughian, F., Akbarzadeh, D., Islampanah, M., Naghsh, N., Abbasalizadeh, M., & Deravi, N. (2022a). Iron Chelators in Treatment of Iron Overload. In *Journal of Toxicology* (Vol. 2022). Hindawi Limited. https://doi.org/10.1155/2022/4911205

Entezari, S., Haghi, S. M., Norouzkhani, N., Sahebnazar, B., Vosoughian, F., Akbarzadeh, D., Islampanah, M., Naghsh, N., Abbasalizadeh, M., & Deravi, N. (2022b). Iron Chelators in Treatment of Iron Overload. In *Journal of Toxicology* (Vol. 2022). Hindawi Limited. https://doi.org/10.1155/2022/4911205

Farashi, S., & Harteveld, C. L. (2018). Molecular basis of α-thalassemia. In *Blood Cells, Molecules, and Diseases* (Vol. 70, pp. 43–53). Academic Press Inc. https://doi.org/10.1016/j.bcmd.2017.09.004

Farmakis, D., Porter, J., Taher, A., Cappellini, M. D., Angastiniotis, M., Eleftheriou, A., Alassaf, A., Angastiniotis, M., Angelucci, E., Aydinok, Y., Bou-Fakhredin Rayan, R., Brunetta, L., Cappellini, M. D., Constantinou, G., Daar, S., De Sanctis, V., Dusheiko, G., Elbard, R., Eleftheriou, A., … Yardumian, A. (2022a). 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. *HemaSphere*, *6*(8). https://doi.org/10.1097/HS9.0000000000000732

Farmakis, D., Porter, J., Taher, A., Cappellini, M. D., Angastiniotis, M., Eleftheriou, A., Alassaf, A., Angastiniotis, M., Angelucci, E., Aydinok, Y., Bou-Fakhredin Rayan, R., Brunetta, L., Cappellini, M. D., Constantinou, G., Daar, S., De Sanctis, V., Dusheiko, G., Elbard, R., Eleftheriou, A., … Yardumian, A. (2022b). 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. *HemaSphere*, *6*(8). https://doi.org/10.1097/HS9.0000000000000732

Farmakis, D., Triposkiadis, F., Lekakis, J., & Parissis, J. (2017). Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management. In *European Journal of Heart Failure* (Vol. 19, Issue 4, pp. 479–489). John Wiley and Sons Ltd. https://doi.org/10.1002/ejhf.708

Fibach, E., & Rachmilewitz, E. A. (2017). Pathophysiology and treatment of patients with beta-thalassemia - an update. In *F1000Research* (Vol. 6). Faculty of 1000 Ltd. https://doi.org/10.12688/f1000research.12688.1

Firdaus, H. F. F., Karnita, R., & Isnaini, W. (2023). *Perancangan Website Sebagai Media Informasi Mengenai Thalassemia Untuk Remaja TUGAS AKHIR*.

Gell, D. A. (2018). Structure and function of haemoglobins. *Blood Cells, Molecules, and Diseases*, *70*, 13–42. https://doi.org/10.1016/J.BCMD.2017.10.006

Gumilang, L., Dewi Judistiani, T., Aryuti Nirmala, S., & Wibowo, A. (2021). *Korelasi Asupan Zat Besi dan Protein dengan Kadar Ferritin Serum Ibu Hamil di Kabupaten Waled dan Sukabumi*. https://doi.org/10.15294/higeia/v2i3/44805

Hartina, M., Politeknik, U., Palembang, K., & Yuliany, E. H. (2017). *KORELASI TRANSFUSI DARAH DENGAN KADAR FERITIN PASIEN THALASSEMIA CORRELATION BLOOD TRANSFUSION AND FERRITIN LEVELS IN PATIENTS WITH THALASSEMIA DISEASE : A LITERATURE REVIEW*. https://www.researchgate.net/publication/340501921

KEMENKES. 2018. PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA THALASEMIA. KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR HK.01.07/MENKES/1/2018. Kementerian Kesehatan Republik Indonesia. Jakarta.

Kontoghiorghes, G. J., Kleanthous, M., & Kontoghiorghe, C. N. (2020). THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA. *Mediterranean Journal of Hematology and Infectious Diseases*, *12*(1), e2020011. https://doi.org/10.4084/mjhid.2020.011

Kowalak, J. P., Welsh, W., & Mayer, B. (2016). *Buku Ajar Patofisiologi.*

Lee, J.-S., Rhee, T.-M., Jeon, K., Cho, Y., Lee, S.-W., Han, K.-D., Seong, M.-W., Park, S.-S., & Lee, Y. K. (2022). Epidemiologic Trends of Thalassemia, 2006–2018: A Nationwide Population-Based Study. *Journal of Clinical Medicine*, *11*(9), 2289. https://doi.org/10.3390/jcm11092289

Lee, W. J., Mohd Tahir, N. A., Chun, G. Y., & Li, S. C. (2024). The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review. In *Health and Quality of Life Outcomes* (Vol. 22, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12955-023-02221-y

Lewandowski, J., Komur, A. A., & Sobańska, D. (2021). Structural and functional relationship of mammalian and nematode ferritins. In *Biotechnologia* (Vol. 102, Issue 4, pp. 457–471). Termedia Publishing House Ltd. https://doi.org/10.5114/BTA.2021.111110

Mahroum, N., Alghory, A., Kiyak, Z., Alwani, A., Seida, R., Alrais, M., & Shoenfeld, Y. (2022). Ferritin – from iron, through inflammation and autoimmunity, to COVID-19. In *Journal of Autoimmunity* (Vol. 126). Academic Press. https://doi.org/10.1016/j.jaut.2021.102778

Mattioli, F., Puntoni, M., Marini, V., Fucile, C., Milano, G., Robbiano, L., Perrotta, S., Pinto, V., Martelli, A., & Forni, G. L. (2015). Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy? *European Journal of Haematology*, *94*(4), 310–317. https://doi.org/10.1111/ejh.12419

Mazzola, M., Crippa, J., Bertoglio, C. L., Andreani, S., Morini, L., Sfondrini, S., & Ferrari, G. (2021). Postoperative risk of pancreatic fistula after distal

pancreatectomy with or without spleen preservation. *Tumori*, *107*(2), 160–165. https://doi.org/10.1177/0300891620936744

Mobarra, N., Shanaki, M., Ehteram, H., Nasiri, H., Sahmani, M., Saeidi, M., Goudarzi, M., Pourkarim, H., & Azad, M. (2016). A Review on Iron Chelators in Treatment of Iron Overload Syndromes. In *International Journal of Hematology-Oncology and Stem Cell Research 5 Review Article IJHOSCR* (Vol. 10, Issue 4).

Nasar, I. M., & Cornain, S. (2015). *Buku Ajar Patologi Robbins* (9th ed.). Elsevier.

Nini, C. (2019). *PENGARUH KADAR FERRITIN SERUM TRANSFUSI DARAH BERULANG TERHADAP GANGGUAN PERTUMBUHAN PADA ANAK THALASSEMIA β MAYOR*.

Nurbahiyah, E., & Maulina, D. (2023). PROFIL PENGGUNAAN OBAT KELASI BESI PADAPASIEN TALASEMIA POLI ANAK DI RUMAH SAKIT X JATINEGARA. In *Indonesian Journal of Health Science* (Vol. 3, Issue 2).

Origa, R. (2017a). β-Thalassemia. In *Genetics in Medicine* (Vol. 19, Issue 6, pp. 609–619). Nature Publishing Group. https://doi.org/10.1038/gim.2016.173

Origa, R. (2017b). β-Thalassemia. *Genetics in Medicine*, *19*(6), 609–619. https://doi.org/10.1038/GIM.2016.173

Panigrahi, M., Swain, T., Jena, R., Panigrahi, A., & Debta, N. (2020). Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha. *Indian Journal of Pharmacology*, *52*(3), 172. https://doi.org/10.4103/ijp.IJP_68_18

Peng, Y. Y., & Uprichard, J. (2017). Ferritin and iron studies in anaemia and chronic disease. In *Annals of Clinical Biochemistry* (Vol. 54, Issue 1, pp. 43–48). SAGE Publications Ltd. https://doi.org/10.1177/0004563216675185

Piolatto, A., Berchialla, P., Allegra, S., De Francia, S., Ferrero, G. B., Piga, A., & Longo, F. (2021). Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. *Scientific Reports*, *11*(1), 12581. https://doi.org/10.1038/s41598-021-91983-w

Plays, M., Müller, S., & Rodriguez, R. (2021). Chemistry and biology of ferritin. In *Metallomics* (Vol. 13, Issue 5). Oxford University Press. https://doi.org/10.1093/mtomcs/mfab021

Porter, D., & Taher, J. (2021). *2021 GUIDELINES FOR THE MANAGEMENT OF TRANSFUSION DEPENDENT THALASSAEMIA (TDT) PUBLISHERS THALASSAEMIA INTERNATIONAL FEDERATION 4 TH EDITION*.

Porter, J. B., & Garbowski, M. (2014). The Pathophysiology of Transfusional Iron Overload. *Hematology/Oncology Clinics of North America*, *28*(4), 683–701. https://doi.org/10.1016/J.HOC.2014.04.003

Reddy, P. S., Locke, M., & Badawy, S. M. (2022). A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia. In *Annals of Medicine* (Vol. 54, Issue 1, pp. 326–342). Taylor and Francis Ltd. https://doi.org/10.1080/07853890.2022.2028894

Rediyanto, D. K. (2023). *Analisis Polimorfieme Gen CYP pada Metabolisme Obat Deteksi Dini Thalassemia* (Vol. 8, Issue 1).

Roemhild, K., Von Maltzahn, F., Weiskirchen, R., Knüchel, R., Von Stillfried, S., & Lammers, T. (2021). Iron metabolism: Pathophysiology and Pharmacology. *Trends Pharmacol Sci.* https://doi.org/10.1016/j.tips.2021.05.001

Rujito, L. (2019a). *Buku Referensi Talasemia : Genetik Dasar dan Pengelolaan Terkini*.

Rujito, L. (2019b). *Buku Referensi Talasemia : Genetik Dasar dan Pengelolaan Terkini*.

Salem, A., Desai, P., & Elgebaly, A. (2023). Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review. *Cureus*. https://doi.org/10.7759/cureus.48276

Sanchez-Villalobos, M., Blanquer, M., Moraleda, J. M., Salido, E. J., & Perez-Oliva, A. B. (2022). New Insights Into Pathophysiology of β-Thalassemia. In *Frontiers in Medicine* (Vol. 9). Frontiers Media S.A. https://doi.org/10.3389/fmed.2022.880752

Sawitri, H., & Asmaul Husna, C. (2018). KARAKTERISTIK PASIEN THALASEMIA MAYOR DI BLUD RSU CUT MEUTIA ACEH UTARA TAHUN 2018. In *Jurnal Averrous* (Vol. 4, Issue 2).

Shafique, F., Ali, S., Almansouri, T., Van Eeden, F., Shafi, N., Khalid, M., Khawaja, S., Andleeb, S., & Ul Hassan, M. (2023). Thalassemia, a human blood disorder. *Brazilian Journal of Biology*, *83*. https://doi.org/10.1590/1519-6984.246062

Shah, F. T., Sayani, F., Trompeter, S., Drasar, E., & Piga, A. (2019). Challenges of blood transfusions in β-thalassemia. In *Blood Reviews* (Vol. 37). Churchill Livingstone. https://doi.org/10.1016/j.blre.2019.100588

Sharma, A., Arora, E., & Singh, H. (2015). Hypersensitivity reaction with deferasirox. *Journal of Pharmacology and Pharmacotherapeutics*, *6*(2), 105–106. https://doi.org/10.4103/0976-500X.155491

Shukla, S. K., Shrivastava, A., & Mishra, P. C. (2019). Effect of deferasirox on serum ferritin level in children with thalassemia major: impact of transfusional iron load. *International Journal of Contemporary Pediatrics*, *6*(5), 2081. https://doi.org/10.18203/2349-3291.ijcp20193729

Sikorska, K., Bernat, A., & Wróblewska, A. (2016). Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis. *Hepatobiliary & Pancreatic Diseases International*, *15*(5), 461–479. https://doi.org/10.1016/S1499-3872(16)60135-2

Suparyanto, T., Anggraeni, M., & Yolandia, R. A. (2023). HUBUNGAN PEMBERIAN TABLET ZINK, GAYA HIDUP, DAN ASUPAN PROTEIN TERHADAP KADAR FERITIN PADA IBU HAMIL TRIMESTER III DI RUMAH SAKIT KRAKATAU MEDIKA CILEGON TAHUN 2022. *SENTRI: Jurnal Riset Ilmiah*, *2*(4).

Supriatna, C., Indriani, B. K., & Akbari, R. (2020). EVALUASI PENGGUNAAN OBAT KELASI BESI DALAM MENURUNK AN
KADAR FERRITIN PADA PASIEN THALASEMIA ANAK DI RSUD 45 KUNINGAN. *Jurnal Ilmiah Indonesia*, *5*.

Supriyanti, E. S. I., & Mariana, M. R. (2019). *Faktor-Faktor Yang Berhubungan Dengan Kepatuhan Transfusi Pada Pasien Thalasemia*.

Susilowati, R. P., Pratanu, L., Ayu, D., & Putri, A. (2024). Case overview of children's thalassemia at RSAB Harapan Kita Jakarta. *Biogenesis: Jurnal Ilmiah Biologi*, *12*(1), 74–80. https://doi.org/10.24252/bio.v12i1.41218

Taher, A. T., Origa, R., Perrotta, S., Kouraklis, A., Ruffo, G. B., Kattamis, A., Goh, A. S., Huang, V., Zia, A., Herranz, R. M., & Porter, J. B. (2018). Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. *Health and Quality of Life Outcomes*, *16*(1). https://doi.org/10.1186/s12955-018-1041-5

Taher, A. T., & Saliba, A. N. (2017). | *EMERGING ISSUES IN CLINICAL CARE IN THALASSEMIA | Iron overload in thalassemia: different organs at different rates.*

Tathe, P. A., Pramod Gosavi, P., & Sanap, G. (2023). *Thalassemia (Beta-Thalassemia)*. www.ijfmr.com

Thein, S. L. (2018). Molecular basis of β thalassemia and potential therapeutic targets. *Blood Cells, Molecules, and Diseases*, *70*, 54–65. https://doi.org/10.1016/J.BCMD.2017.06.001

Tripathy, I., Panja, A., Dolai, T. K., & Mallick, A. K. (2021). Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children. *Hemoglobin*, *45*(5), 296–302. https://doi.org/10.1080/03630269.2021.1999258

Tuo, Y., Li, Y., Li, Y., Ma, J., Yang, X., Wu, S., Jin, J., & He, Z. (2024). Global, regional, and national burden of thalassemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. *EClinicalMedicine*, *72*. https://doi.org/10.1016/j.eclinm.2024.102619

Viprakasit, V., & Ekwattanakit, S. (2018). Clinical Classification, Screening and Diagnosis for Thalassemia. In *Hematology/Oncology Clinics of North America* (Vol. 32, Issue 2, pp. 193–211). W.B. Saunders. https://doi.org/10.1016/j.hoc.2017.11.006

Vlachaki, E., Bakır Koyuncu, M., Salido, E. J., Perez-Oliva, A. B., Sanchez-Villalobos, M., Blanquer, M., & Moraleda, J. M. (2022). New Insights Into Pathophysiology of β-Thalassemia. *Frontiers in Medicine | Www.Frontiersin.Org*, *1*, 880752. https://doi.org/10.3389/fmed.2022.880752

Yampayon, K., Anantachoti, P., Chongmelaxme, B., & Yodsurang, V. (2023). Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis. *Frontiers in Pharmacology*, *14*. https://doi.org/10.3389/fphar.2023.1069854

Yiannikourides, A., & Latunde-Dada, G. (2019). A Short Review of Iron Metabolism and Pathophysiology of Iron Disorders. *Medicines*, *6*(3), 85. https://doi.org/10.3390/medicines6030085

Yusuf, S., Herdata, H. N., Edward, E. D., & Khairunnisa, K. (2023). Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes. *F1000Research*, *12*, 154. https://doi.org/10.12688/f1000research.128810.1